Author: Mayla Borba; Fernando de Almeida Val; Vanderson Sousa Sampaio; Marcia Araujo Alexandre; Gisely Cardoso Melo; Marcelo Brito; Maria Mourao; Jose Diego Brito Sousa; djane Baia-da-Silva; Marcus Vinitius Farias Guerra; Ludhmila Hajjar; Rosemary Costa Pinto; Antonio Balieiro; Felipe Gomes Naveca; Mariana Xavier; Alexandre Salomao; Andre Siqueira; Alexandre Schwarzbolt; Julio Henrique Rosa Croda; Mauricio Lacerda Nogueira; Gustavo Romero; Quique Bassat; Cor Jesus Fontes; Bernardino Albuquerque; Claudio Daniel-Ribeiro; Wuelton Monteiro; Marcus Lacerda
Title: Chloroquine diphosphate in two different dosages as adjunctive therapy of hospitalized patients with severe respiratory syndrome in the context of coronavirus (SARS-CoV-2) infection: Preliminary safety results of a randomized, double-blinded, phase IIb clinical trial (CloroCovid-19 Study) Document date: 2020_4_11
ID: ifxm3j4y_89
Snippet: Major limitations however included: (1) one single center; (2) not using a placebo control group as the use of placebo in Brazil in severe cases of COVID-19 infections is not considered ethically acceptable by national regulatory health agencies, especially due to the compassionate use of CQ -and because early reports seem to indicate its effectiveness in vitro and in vivo......
Document: Major limitations however included: (1) one single center; (2) not using a placebo control group as the use of placebo in Brazil in severe cases of COVID-19 infections is not considered ethically acceptable by national regulatory health agencies, especially due to the compassionate use of CQ -and because early reports seem to indicate its effectiveness in vitro and in vivo.
Search related documents:
Co phrase search for related documents- early report and single center: 1, 2
- health agency and national regulatory health agency: 1, 2, 3
- health agency and placebo control: 1
- health agency and placebo control group: 1
- health agency and regulatory health agency: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
- health agency and severe case: 1
- health agency and single center: 1, 2, 3
- infection severe case and severe case: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73
- infection severe case and single center: 1, 2, 3
- major limitation and placebo control: 1
- major limitation and placebo control group: 1
- major limitation and single center: 1
- national regulatory health agency and regulatory health agency: 1, 2, 3
- placebo control and single center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- placebo control group and single center: 1, 2, 3, 4, 5, 6
- regulatory health agency and single center: 1
- severe case and single center: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
Co phrase search for related documents, hyperlinks ordered by date